CN101417100A - 一种治疗继发性肺结核的药物及制备方法 - Google Patents
一种治疗继发性肺结核的药物及制备方法 Download PDFInfo
- Publication number
- CN101417100A CN101417100A CNA2008103060526A CN200810306052A CN101417100A CN 101417100 A CN101417100 A CN 101417100A CN A2008103060526 A CNA2008103060526 A CN A2008103060526A CN 200810306052 A CN200810306052 A CN 200810306052A CN 101417100 A CN101417100 A CN 101417100A
- Authority
- CN
- China
- Prior art keywords
- parts
- portions
- radix
- medicine
- pulmonary tuberculosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 239000003814 drug Substances 0.000 title claims description 41
- 208000008128 pulmonary tuberculosis Diseases 0.000 title claims description 31
- 229940079593 drug Drugs 0.000 title claims description 12
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 15
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 15
- 241000545442 Radix Species 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 13
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000002481 ethanol extraction Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 210000004072 lung Anatomy 0.000 abstract description 16
- 206010011224 Cough Diseases 0.000 abstract description 15
- 206010036790 Productive cough Diseases 0.000 abstract description 13
- 208000024794 sputum Diseases 0.000 abstract description 11
- 210000003802 sputum Anatomy 0.000 abstract description 11
- 208000024891 symptom Diseases 0.000 abstract description 10
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 7
- 208000026435 phlegm Diseases 0.000 abstract description 7
- 238000006243 chemical reaction Methods 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 6
- 230000000740 bleeding effect Effects 0.000 abstract description 5
- 230000001502 supplementing effect Effects 0.000 abstract description 5
- 238000002512 chemotherapy Methods 0.000 abstract description 4
- 201000008827 tuberculosis Diseases 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 2
- 241001313857 Bletilla striata Species 0.000 abstract 1
- 241000935235 Fritillaria meleagris Species 0.000 abstract 1
- 235000013717 Houttuynia Nutrition 0.000 abstract 1
- 240000000691 Houttuynia cordata Species 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 241000234435 Lilium Species 0.000 abstract 1
- 229930195210 Ophiopogon Natural products 0.000 abstract 1
- 244000248557 Ophiopogon japonicus Species 0.000 abstract 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 abstract 1
- 240000003582 Platycodon grandiflorus Species 0.000 abstract 1
- 241000218206 Ranunculus Species 0.000 abstract 1
- 241001671204 Stemona Species 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000002398 materia medica Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000008267 milk Substances 0.000 abstract 1
- 210000004080 milk Anatomy 0.000 abstract 1
- 235000013336 milk Nutrition 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 239000011148 porous material Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 description 13
- 239000003172 expectorant agent Substances 0.000 description 12
- 230000003419 expectorant effect Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 230000007812 deficiency Effects 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 8
- 230000008961 swelling Effects 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 4
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229940000406 drug candidate Drugs 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 206010029410 night sweats Diseases 0.000 description 4
- 230000036565 night sweats Effects 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 4
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 4
- 235000021286 stilbenes Nutrition 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 208000000616 Hemoptysis Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000000954 anitussive effect Effects 0.000 description 3
- 229940124584 antitussives Drugs 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 238000007373 indentation Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010063659 Aversion Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960005206 pyrazinamide Drugs 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (5)
- 【权利要求1】一种治疗继发性肺结核的药物,其特征在于由以下重量原料药制成:黄芪120~180份、百合60~90份、麦冬60~90份、平贝母45~75份、鱼腥草90~135份、胡黄连90~135份、猫爪草75~110份、百部90~135份、桔梗60~90份、三七30~45份、白及60~90份。
- 【权利要求2】按照权利要求1所述的治疗继发性肺结核的药物,其特征在于黄芪150份、百合75份、麦冬75份、平贝母60份、鱼腥草112.5份、胡黄连112.5份、猫爪草90份、百部112.5份、桔梗75份、三七37.5份、白及75份。
- 【权利要求3】按照权利要求1或2所述的治疗继发性肺结核的药物,其特征在于剂型为片剂、胶囊、颗粒剂、丸剂或口服液。
- 【权利要求4】按照权利要求3所述的治疗继发性肺结核的药物,其特征在于加入药学上不同剂型可接受的辅料制成。
- 【权利要求5】一种如权利要求1或2所述的治疗继发性肺结核药物的制备方法,其特征在于步骤如下:(1)三七、白及粉碎成细粉;(2)平贝母、百部、鱼腥草加70%乙醇提取2次,第一次2.0小时,第二次1.0小时,合并提取液,回收乙醇,浓缩成清膏;(3)步骤(2)得到的药渣与其余黄芪等六味加水煎煮二次,每次1.0小时,合并煎液,滤过,得滤液,滤液与步骤(2)得到的清膏合并,浓缩至相对密度为1.30~1.32的清膏,加入三七、白及细粉,混匀,干燥,粉碎成细粉,制成药剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008103060526A CN101417100B (zh) | 2008-12-09 | 2008-12-09 | 一种治疗继发性肺结核的药物及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008103060526A CN101417100B (zh) | 2008-12-09 | 2008-12-09 | 一种治疗继发性肺结核的药物及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101417100A true CN101417100A (zh) | 2009-04-29 |
CN101417100B CN101417100B (zh) | 2011-04-06 |
Family
ID=40628226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008103060526A Active CN101417100B (zh) | 2008-12-09 | 2008-12-09 | 一种治疗继发性肺结核的药物及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101417100B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101850084A (zh) * | 2010-05-31 | 2010-10-06 | 哈尔滨华雨制药集团有限公司 | 治疗肺结核的中药组合物及其制备方法 |
CN105687734A (zh) * | 2016-03-01 | 2016-06-22 | 姜静 | 一种治疗继发性肺结核的中药及其制备方法 |
CN105816769A (zh) * | 2016-05-19 | 2016-08-03 | 通化吉通药业有限公司 | 贝芪益肺片及鉴别和含量测定方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101116733B (zh) * | 2006-08-04 | 2011-10-12 | 张立梅 | 一种治疗肺结核病的清肺祛痨丸 |
CN101129904B (zh) * | 2006-08-25 | 2011-08-03 | 张立梅 | 一种治疗结核性胸膜炎、腹膜炎、脓胸和支气管胸膜瘘的清胸祛痨丸 |
-
2008
- 2008-12-09 CN CN2008103060526A patent/CN101417100B/zh active Active
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101850084A (zh) * | 2010-05-31 | 2010-10-06 | 哈尔滨华雨制药集团有限公司 | 治疗肺结核的中药组合物及其制备方法 |
CN101850084B (zh) * | 2010-05-31 | 2012-11-28 | 哈尔滨华雨制药集团有限公司 | 治疗肺结核的中药组合物及其制备方法 |
CN105687734A (zh) * | 2016-03-01 | 2016-06-22 | 姜静 | 一种治疗继发性肺结核的中药及其制备方法 |
CN105816769A (zh) * | 2016-05-19 | 2016-08-03 | 通化吉通药业有限公司 | 贝芪益肺片及鉴别和含量测定方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101417100B (zh) | 2011-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102698097B (zh) | 用于治疗牙周炎的中药组合物、其剂型、制备方法和牙膏 | |
CN102205107B (zh) | 一种治疗十二指肠溃疡的中药制剂及其制备方法 | |
CN102698122B (zh) | 用于治疗牙周炎的中药、制备方法、牙膏和给药方式 | |
US20110104290A1 (en) | Compositions for reducing blood glucose level and uses thereof | |
CN107260963A (zh) | 以铁皮石斛与莱菔子为主材制备治疗高血压药物的方法 | |
CN101062356A (zh) | 一种治疗小儿遗尿的中药 | |
CN101417100B (zh) | 一种治疗继发性肺结核的药物及制备方法 | |
CN104435837B (zh) | 一种治疗自汗、盗汗的药物组合物 | |
CN103041341A (zh) | 用于治疗结核性渗出性胸膜炎的中药组合物及其制备方法 | |
CN110368445A (zh) | 一种治疗银屑病的中药组合物及其制备方法和应用 | |
CN102579999A (zh) | 一种治疗癌性发热的药物及其制备方法 | |
CN104324261A (zh) | 治疗高血糖的药物组合物及其制备方法 | |
CN104623583A (zh) | 一种治疗虚寒腹痛的药物及其口服液制备方法 | |
CN103393938B (zh) | 一种降血糖的中药组合物 | |
CN102552677B (zh) | 黄地安消胶囊及其制备方法 | |
CN103495115B (zh) | 一种对糖尿病具有治疗作用的药酒 | |
CN102988747B (zh) | 一种三刺降三高的冲剂及其制备方法 | |
CN105168892A (zh) | 一种用于治疗低血糖症的中药制剂及制备方法 | |
CN104367753A (zh) | 一种治疗2型糖尿病的中药组合物 | |
CN104687032A (zh) | 一种保护健康的紫锥菊保健品 | |
CN103223107A (zh) | 一种用于调节血脂血压的中药及其制备工艺 | |
CN102526248B (zh) | 一种治疗糖尿病伤口溃烂并可持续降血糖的中药组合物 | |
CN105943860A (zh) | 一种用于治疗糖尿病的药物制剂及其制备方法 | |
CN105853717A (zh) | 一种用于治疗ⅱ型糖尿病的中成药 | |
CN104352987A (zh) | 一种治疗心肝火旺证型甲亢的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CB03 | Change of inventor or designer information |
Inventor after: Yang Jing Inventor after: Chen Yihuan Inventor before: Yang Jing |
|
COR | Change of bibliographic data | ||
CP01 | Change in the name or title of a patent holder |
Address after: 134001 Tonghua city of Jilin Province Dongchang District Xinming Road No. 555 Patentee after: TONGHUA JITONG PHARMACEUTICAL Co.,Ltd. Address before: 134001 Tonghua city of Jilin Province Dongchang District Xinming Road No. 555 Patentee before: TONGHUA YONGCANG PHARMACEUTICAL Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A drug for the treatment of secondary pulmonary tuberculosis and its preparation method Effective date of registration: 20200812 Granted publication date: 20110406 Pledgee: Tonghua Branch of China Everbright Bank Co.,Ltd. Pledgor: TONGHUA JITONG PHARMACEUTICAL Co.,Ltd. Registration number: Y2020980004883 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220622 Granted publication date: 20110406 Pledgee: Tonghua Branch of China Everbright Bank Co.,Ltd. Pledgor: TONGHUA JITONG PHARMACEUTICAL Co.,Ltd. Registration number: Y2020980004883 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A drug for treating secondary pulmonary tuberculosis and its preparation method Effective date of registration: 20220624 Granted publication date: 20110406 Pledgee: Tonghua Branch of China Everbright Bank Co.,Ltd. Pledgor: TONGHUA JITONG PHARMACEUTICAL Co.,Ltd. Registration number: Y2022220000022 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230621 Granted publication date: 20110406 Pledgee: Tonghua Branch of China Everbright Bank Co.,Ltd. Pledgor: TONGHUA JITONG PHARMACEUTICAL Co.,Ltd. Registration number: Y2022220000022 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A drug and preparation method for treating secondary pulmonary tuberculosis Effective date of registration: 20230628 Granted publication date: 20110406 Pledgee: Tonghua Branch of China Everbright Bank Co.,Ltd. Pledgor: TONGHUA JITONG PHARMACEUTICAL Co.,Ltd. Registration number: Y2023220000042 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |